FDA 483 - Sai Life Sciences Limited

An FDA inspection of Sai Life Sciences Limited in Bidar, India, revealed significant deficiencies in their quality system. The firm failed to adequately investigate unexplained discrepancies, including the proper identification of foreign particles in manufacturing materials and the complete documentation of maintenance activities. These issues indicate a lack of robust quality control and record-keeping practices.